Adverse events were consistent with the known safety profiles of each medication.1,2
Most common adverse reactions (≥ 20% incidence) in Isa-Kd vs Kd arms1,2
The most frequent serious adverse reactions in > 5% of patients who received Isa-Kd were pneumonia (25%) and upper respiratory tract infections (9%).
Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone; Kd = carfilzomib + dexamethasone; AE = adverse event.
References: 1. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361-2371. 2. SARCLISA® (isatuximab-irfc) prescribing information. Bridgewater, NJ: sanofi-aventis U.S. LLC.